Clinical Trial Update: Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 safety study evaluating the combination of azacitidine with donor lymphocyte infusion for relapsed acute myeloid leukemia or myelodysplastic syndrome af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Donor Lymphocyte Infusion

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED